Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Potentiator potential

Why Pfizer Venture Investments led Effector's $38.6M series C

Preclinical data showing how eFT508 could fit into checkpoint inhibitor cocktails helped Effector Therapeutics Inc. snag Pfizer Inc. (NYSE:PFE) as both a development partner and an investor.

On July 24, Effector closed a $19.3 million first tranche of a $38.6 million

Read the full 418 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE